ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) disclosed a share buyback conducted on 26 June 2026, repurchasing 93,400 H shares on the Hong Kong Stock Exchange.

The shares were bought at prices ranging between HKD 3.60 and HKD 3.74, with a volume-weighted average cost of HKD 3.663, bringing the aggregate consideration to HKD 342,122. The repurchased shares have been retained as treasury stock.

Following the transaction, the company’s issued share capital (excluding treasury shares) declined by 0.02 % to 419.04 million shares. Treasury shares increased to 1.44 million, while total issued shares remained unchanged at 420.48 million.

The repurchase falls under the mandate approved on 28 May 2026, which authorises buybacks of up to 43.15 million shares. Cumulative repurchases under this mandate now stand at 1.44 million shares, equivalent to 0.33 % of the issued share base on the mandate date.

Under Hong Kong listing rules, IMMUNEONCO-B is subject to a 30-day moratorium on new share issues or sales of treasury shares, lasting until 26 July 2026.